title: In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
abstract: Ceftobiprole is an investigational intravenous broad-spectrum cephalosporin with in vitro activity against Gram-positive and Gram-negative pathogens, including meticillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Pseudomonas aeruginosa is a frequent nosocomial pathogen, increasingly associated with complicated skin and skin-structure infections. Combination antimicrobial therapy is recommended as empirical therapy for serious infections where P. aeruginosa is suspected. Therefore, in this study the interaction of ceftobiprole with two other antipseudomonal agents (amikacin and levofloxacin) was investigated. Time-kill studies were performed for each single agent and for the combination of ceftobiprole 4 mg/L with either amikacin or levofloxacin at 0.5×, 1× and 2× the minimum inhibitory concentration. Five clinical isolates of P. aeruginosa as well as the P. aeruginosa ATCC 27853 reference strain were tested at initial inocula of 5×10(5) colony-forming units (CFU)/mL (low inoculum) or 5×10(7) CFU/mL (high inoculum). Synergy was defined as a decrease of ≥2log(10) CFU/mL with the combination compared with the most active single drug at 6 h and 24 h. At low inoculum with ceftobiprole as a single agent, viable counts were decreased by 1.5-2log(10) at 6 h. Addition of either amikacin or levofloxacin resulted in synergistic bactericidal activity at 24 h. At high inoculum the combination of ceftobiprole with amikacin or levofloxacin demonstrated synergism in one of three and three of five strains, respectively. This study demonstrated that the combination of ceftobiprole at a clinically achievable concentration of 4 mg/L with amikacin or levofloxacin exhibited synergistic activity against P. aeruginosa. There was no evidence of antagonism for either combination.
authors.affiliation: Antiinfectives Intelligence GmbH, Campus of the University of Applied Sciences Bonn-Rhein-Sieg, Von-Liebig-Straße 20, 53359 Rheinbach, Germany. michael.kresken@antiinfectives-intelligence.de
authors.forename: Michael
authors.initials: M
authors.lastname: Kresken
authors.forename: Barbara
authors.initials: B
authors.lastname: Körber-Irrgang
authors.forename: Jörg
authors.initials: J
authors.lastname: Läuffer
authors.forename: Sabine
authors.initials: S
authors.lastname: Decker-Burgard
authors.forename: Todd
authors.initials: T
authors.lastname: Davies
mesh_terms: D000583:Amikacin / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development; D013234:Stem Cells; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole; D064704:Levofloxacin; D000583:Amikacin; D015242:Ofloxacin